1 / 2

SDB-005(2180934-13-6)-APICDMO-20230419

APICDMO is the professional manufacturer of SDB-005 and accept Synthetic customization. These products are for scientific research purposes only and not for sale to individuals.<br><br>SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.<br><br>https://www.apicdmo.com/product/2180934-13-6/

apicdmo
Télécharger la présentation

SDB-005(2180934-13-6)-APICDMO-20230419

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SDB-005 CAS:2180934-13-6 APICDMO is the professional manufacturer of SDB-005 and accept Synthetic customization. These products are for scientific research purposes only and not for sale to individuals. What is SDB-005? SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group. The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM). SDB-005(2180934-13-6) Information Product Name CAS Number Formula Molar mass PubChem CID ChemSpider UNII SDB-005 2180934-13-6 C23H22N2O2 358.441 g·mol−1 125181303 30922481 Z6XWV5U765 However, indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name.Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005. SDB-005 was subsequently used as the name for the www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

  2. Reference [1] “SDB-005”. Cayman Chemical. Retrieved 27 June 2015. [2] Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). “The synthesis and adamantane-derived indoles: cannabimimetic drugs of abuse”. ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277. pharmacological evaluation of [3] EWS_EU: Neue Psychoaktive Substanzen, April 2015 www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

More Related